Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) FCF Margin (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed FCF Margin for 11 consecutive years, with 200.92% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 3213.0% to 200.92% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 334.22% through Dec 2025, down 31068.0% year-over-year, with the annual reading at 334.53% for FY2025, 31099.0% down from the prior year.
  • FCF Margin hit 200.92% in Q4 2025 for Voyager Therapeutics, up from 233.86% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 5226.14% in Q1 2022 to a low of 2770.65% in Q2 2022.
  • Historically, FCF Margin has averaged 129.19% across 5 years, with a median of 157.83% in 2025.
  • Biggest five-year swings in FCF Margin: surged 555395bps in 2022 and later plummeted -514410bps in 2023.
  • Year by year, FCF Margin stood at 39.67% in 2021, then soared by 1640bps to 690.32% in 2022, then tumbled by -104bps to 27.21% in 2023, then plummeted by -757bps to 233.04% in 2024, then grew by 14bps to 200.92% in 2025.
  • Business Quant data shows FCF Margin for VYGR at 200.92% in Q4 2025, 233.86% in Q3 2025, and 660.88% in Q2 2025.